{"id":"NCT00224133","sponsor":"Watson Pharmaceuticals","briefTitle":"The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months","officialTitle":"A Multi-Center, Open-Label Evaluation of the Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-09","primaryCompletion":"2007-04","completion":"2007-04","firstPosted":"2005-09-22","resultsPosted":"2010-04-27","lastUpdate":"2010-04-27"},"enrollment":661,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Benign Prostatic Hyperplasia"],"interventions":[{"type":"DRUG","name":"Silodosin","otherNames":["Rapaflo"]}],"arms":[{"label":"Silodosin","type":"EXPERIMENTAL"}],"summary":"A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.","primaryOutcome":{"measure":"Adverse Events","timeFrame":"9 months","effectByArm":[{"arm":"8 mg Silodosin Per Day With Food","deltaMin":431,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":79,"countries":["United States"]},"refs":{"pmids":["19815265"],"seeAlso":["http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails"]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":661},"commonTop":["Retrograde ejaculation"]}}